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Abstract 
Background: Invasive lobular breast cancer (ILC) accounts for ~15% of invasive breast 
carcinomas and is commonly associated with lobular carcinoma in situ (LCIS). Both have 
been shown to have higher familial risks than the more common ductal cancers. However 
there is little data on the prevalence of the known high and moderate penetrance breast 
cancer predisposition genes in ILC. The aim of this study was to assess the frequency of 
germline variants in CDH1, BRCA2, BRCA1, CHEK2, PALB2 and TP53 in sporadic ILC and 
LCIS diagnosed in women aged 60 years or less.  
Methods: Access Array technology (Fluidigm) was used to amplify all exons of CDH1, 
BRCA2, BRCA1, TP53, CHEK2 and PALB2 using a custom made targeted sequencing 
panel in 1,434 cases of ILC and 368 cases of pure LCIS together with 1,611 controls.  
Results: Case-control analysis revealed an excess of pathogenic variants in BRCA2, 
CHEK2, PALB2 and CDH1 in women with ILC. CHEK2 was the only gene that showed an 
association with pure LCIS (OR = 9.90, 95% CI 3.42-28.66, P = 1.4 x10-5) with a larger effect 
size seen in LCIS compared to ILC (OR = 4.31, 95% CI 1.61-11.58, P = 1.7 x10-3).  
Conclusions: 11% of patients with ILC aged </= 40 years carried germline variants in 
known breast cancer susceptibility genes. 
Impact: Women with ILC aged of 40 years or less should be offered genetic screening using 
a panel of genes that includes BRCA2, CHEK2, PALB2 and CDH1. 
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Introduction 
Invasive lobular breast cancer (ILC) accounts for ~15% of invasive breast cancer. Its 
incidence has increased, in line with the greater use of combined hormone replacement 
therapy until the late 1990s (1,2). ILC is commonly associated with lobular carcinoma in situ 
(LCIS), which is considered both a precursor lesion and a risk factor for invasive breast 
cancer. The risk of invasive cancer after LCIS is 2-11 times greater than the risk in general 
population resulting in a cumulative long-term rate of invasive cancer of 11-26% at 15 years,  
in contrast to ductal carcinoma in situ (DCIS) which is 20 times greater (3,4). Not all invasive 
disease post LCIS presents as ILC, although there is an excess of ILC. Molecular studies of 
co-existing invasive ductal carcinoma (IDC)/ DCIS and LCIS identified similar genomic 
alterations, suggesting that in some cases they may have a common clonal origin (5,6). 
Unlike DCIS, LCIS is also a risk factor for developing invasive cancer in the contralateral 
breast (7). The underlying biological cause for this is not clear.  
 
Both ILC and LCIS have been shown to have higher familial risks than the more common 
ductal/no special type cancers and are more likely to be bilateral (8-10). We have previously 
shown that many of the low risk breast cancer predisposition loci also predispose to ILC and 
LCIS, with some differential effects between ILC and IDC (11). We also have identified a 
novel lobular-specific predisposition SNP at 7q34. However, there is little data on the 
prevalence of the known high and moderate penetrance breast cancer predisposition genes 
in lobular breast cancer, with the exception of CDH1 as lobular carcinomas are 
characterised by loss of E-cadherin expression (the protein encoded by CDH1) through 
somatic alterations. Germline CDH1 variants were initially reported in hereditary diffuse 
gastric cancer (HDGC) (12) and about 30% of HDGC families with a CDH1 germline variant 
typically have at least one individual with ILC (13-16). However germline CDH1 variants in 
women with ILC and no family history of HDGC are not common (17-20), although there is 
some evidence that bilateral cases of LCIS + / - ILC have a higher incidence of germline 
CDH1 pathogenic variants (21).  
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Lobular cancers have been shown to be more frequent among BRCA2 carriers (8.4%) than 
BRCA1 carriers (2.2%) (22) and there is scanty evidence that CHEK2 and PALB2 variants 
may be associated with ILC (23,24). BRCA1 and TP53 are not well described in ILC. 
 
In this study we report the frequency of rare variants in six known breast cancer 
predisposition genes (CDH1, BRCA2, BRCA1, TP53, CHEK2, and PALB2) in 1802 sporadic 
UK lobular cancers diagnosed in the UK in women aged 60 years or less.  
 
Materials and Methods 
Samples 
All patients and controls gave written informed consent and the studies were conducted in 
accordance with the  Declaration of Helsinki and were approved by the following institutional 
review boards:  GLACIER study, MREC 06/Q1702/64; King’s Health Partners breast tissue 
bank, NHS REC ref. 12-EE-0493. 
 
1,434 cases of ILC (with or without synchronous LCIS) and 368 cases of pure LCIS with no 
invasive disease diagnosed in women aged 60 or under were included in this study, together 
with 1,611 controls, between 6/6/2007 – 28/08/2012 (prevalent cases). Bilateral cases were 
eligible including those with ILC in one breast and IDC in the contralateral breast. The 
majority of cases (1380 ILC, 364 LCIS) were recruited through the GLACIER study from 95 
hospitals throughout the UK. This study was set up with the specific aim of investigating 
genetic predisposition to lobular cancer in the UK. These samples were also part of our 
study of low risk breast cancer loci in lobular breast cancer (11). A further 58 cases, 
including four pure LCIS were recruited through the King’s Health Partners (KHP) breast 
tissue bank. Cases aged 60 or under were collected in order to enrich for cases likely to 
have a genetic component to their disease.  
 
 5 
 
 
Controls were identified by asking cases at the time of recruitment to identify female non-
blood relatives or friends who were willing to donate a blood sample. These healthy 
volunteers were only eligible if they had no personal or family (up to 2nd degree) history of 
breast cancer, LCIS, DCIS or benign breast disease. Controls could be of any age, although 
older individuals were preferred, as they had lived through many of their at-risk years. 
 
Cases and controls donated a blood sample and were asked to complete a self-
administered paper-based questionnaire on their family history at the time of recruitment.  
 
Next-Generation Sequencing 
After DNA extraction from peripheral blood, Access Array technology (Fluidigm) was used to 
amplify all exons of CDH1, BRCA2, BRCA1, TP53, CHEK2 and PALB2 using a custom 
made targeted sequencing panel consisting of 321 amplicons (Supplementary Table 1). 
Purified libraries were quantified using Qubit High Sensitivity Assay Kit and sequenced on a 
HiSeq2500 (Illumina). 
 
Bioinformatics Analysis 
Primer sites from the amplicons were trimmed using Btrim and then sequences were aligned 
to the reference genome (http://www.novocraft.com, GRCh37 version) using Novoalign (Gap 
opening penalty = 65 and gap extension penalty = 7 thresholds were applied). Picard tools 
(v1.74 https://github.com/broadinstitute/picard) and Bedtools (v2.17.0) were used to assess 
coverage. Variant calling was performed using Samtools and annotated using the Annovar 
tool (25). We optimised the calling based on a set of variants that were positive controls and 
samtools was the optimal caller compared to HaplotypeCaller from GATK. The transcript 
that was used for each gene is reported in Supplementary Table 1. The frequency of 
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variant alleles from European reference populations was obtained from three sources (1000 
genomes, ESP, ExAC). 
 
Variants were further filtered based on read depth, quality score, and genotypic quality. All 
variants with a read depth < 10, quality score < 20, or genotypic score < 20 were excluded 
from the analysis. In addition, variants with an allelic ratio < 0.2 were excluded irrespective of 
read depth and variants with an allelic ratio < 0.3   and read depth < 50 were also removed. 
 
 Variants that had been previously clinically evaluated and reposited in the ClinVar database 
(https://www.ncbi.nlm.nih.gov/clinvar/) , were assigned labels of benign, variants of unknown 
significance (VUS), conflicting or pathogenic as per ClinVar. 
 
Variants not present in the ClinVar database were considered pathogenic if they were 
predicted to lead to protein truncation (frameshift indels, stop-gain, stop-loss and splicing 
variants within 2 base pairs of the splicing junction, Supplementary Table 2) and VUS if 
they were nonsynonymous substitutions or in-frame indels.  
 
Statistical analysis 
Fisher’s exact test was used for gene based rare variant analysis for both case control and 
case only analyses. One sided test was selected since the expectation was enrichment 
rather than deficit of variants in cases over controls. No adjustments have been made to 
account for multiple testing. With the current sample size of ILC and controls we have more 
than 80% power (alpha =0.05) to detect variants of combined allele frequency =0.001 and 
an effect size of OR = 5. 
 
Validation 
All putative pathogenic alleles and CHEK2 1100delC variants, identified by the above 
methods were confirmed by Sanger sequencing, Supplementary Figure1. 
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Results 
1,434 cases of ILC (with or without synchronous LCIS), 368 cases of pure LCIS (with no 
invasive disease) together with 1,611 controls were analysed. The median age of cases was 
52 years (interquartile range 9) and of controls was 52 (interquartile range 12), 
Supplementary Table 3. The mean coverage of our target region was 800 reads across all 
samples, with an average of at least 40 reads for more than 98% of the target region per 
sample. Of the 321 amplicons analysed seven failed to amplify consistently across the 
majority of the samples, however even for these seven the majority of samples had at least 
10 reads for 90% of the amplicon, Supplementary Table 4. There was one novel 
pathogenic variant (PALB2:exon5:c.2487delG) that did not validate by Sanger Sequencing 
as there was no further DNA available. 
 
Case-control analysis of the 1,434 cases of ILC and 1,611 controls revealed an association 
with putative pathogenic variants in BRCA2, CDH1, CHEK2 and PALB2.  No association of 
putative pathogenic variants was observed in BRCA1 or TP53, Table 1, Supplementary 
Table 5.  
 
BRCA2 
The strongest evidence of association was with BRCA2, which contained 27 putative 
pathogenic variants in 1,434 cases and two in 1,611 controls (OR = 15.44, 95% CI 3.66-
65.04, P = 1.7.0 x10-7). Variants were spread throughout the gene, Figure 1a. Five were 
novel (Supplementary Table 6) two located in exon 11, one in exon 22 and two in exon 27. 
The novel frameshifts in exon 27 although unlikely to result in loss of function through 
nonsense mediated decay may have substantial impact on the protein product and were 
included as putative pathogenic variants. The two controls with pathogenic BRCA2 variants 
were recruited at the age of 41 and 43 years; both were in exon 11 and have been described 
previously: rs80359550: c.5946delT: p.S1982fs and rs397507634: c.C2612A: p.S871X. 
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Case only analysis showed that BRCA2 variants were more common in younger patients; 7% 
of women with ILC =/< 40 years of age were carriers and 3.4% of women =/< 50 years (case 
only analysis: =/< 50 years vs > 50 years: OR = 4.83, 95% CI 1.95-12.01, P = 0.0003, Table 
2a). The majority (16/27; 59%) of carriers presented with ILC between 40-50 years of age. 
There was a borderline association with 1st degree family history of breast cancer (case only 
analysis OR = 2.36, 95% CI 1.05-5.31, P = 0.043) and any family history of breast cancer (OR 
= 2.25, 95% CI 1.02-4.98, P = 0.046), Table 2b. One case of pure LCIS had a BRCA2 stop-
gain variant in exon 25, c.C9294G:p.Y3098X. Case only analysis showed a significant 
association of BRCA2 pathogenic variants with ILC compared to LCIS (P=0.03, Table 1) 
  
CHEK2  
Nineteen cases of ILC and five controls, OR = 4.31, 95% CI 1.61-11.58, P = 0.0017, 
Supplementary Table 7, had pathogenic variants in CHEK2. Seventeen cases had known 
pathogenic variants, two with the recently described Norwegian variant: c.C283T:p.R95X, 
(both bilateral); two at c.349A>G (p.Arg117Gly) and the majority (N = 13) being the well 
described 1100delC variant. A novel frameshift variant in exon 12 (c.1262delT:p.L421fs) was 
found in two cases. Four controls also had the 1100delC variant and one a splicing variant in 
exon15:(c.1462-2A>G). No pathogenic variants were found in women under the age of 40 
and there was no association with age (case only analysis: =/< 50 years vs > 50 years: OR = 
0.78, 95% CI 0.31-1.99, P = 0.65) or 1st degree family history of breast cancer (case only 
analysis OR = 2.59, 95% CI 1.02-6.60, P = 0.067), Table 2b. However, a significant excess 
of variants was observed in individuals with any family history of breast cancer (OR = 3.95, 
95% CI 1.42-11.01, P = 0.008). 
 
There was also an association with pure LCIS (OR = 9.90, 95% CI 3.42-28.66, P = 1.4 x10-
5), Table 1. Eleven cases had CHEK2 variants of which eight were the 1100delC variant, 
one was the c.C283T:p.R95X variant and there were two novel variants: a frame shift in 
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exon 2 (c.188_189insC:p.L63fs) and a stop gain in exon 6 (c.G697T:p.E233X). Case only  
analysis revealed that  CHEK2 variants were more strongly associated with LCIS then ILC 
(ILC vs LCIS, P = 0.037, Table 1). Assessment of the pathology reports revealed that 17/19 
ILC cases with pathogenic CHEK2 variants had associated LCIS identified by the 
pathologists. Combining the ILC and LCIS cases gives an overall OR of 5.42 (95% CI 2.10-
13.99, P = 6x10-5) for lobular breast cancer.  
 
PALB2 
Eleven cases of ILC had pathogenic PALB2 variants, of which seven were novel (OR = 
12.45, 95% CI1.60-95.52, P = 0.002), Supplementary Table 8. One control also carried a 
novel frameshift variant (exon5:c.2050delC:p.P684fs). Like CHEK2 there was no evidence of 
association with age (all cases were over 40 years old at diagnosis and six were over 50 
(case only analysis: =/< 50 years vs > 50 years OR = 1.12 95% CI 0.34-3.68, P = 0.99), or 
with family history of breast cancer, Table 2. There was one case of pure LCIS with a 
germline PALB2 variant in exon 10, c.G3113A:p.W1038X. 
 
CDH1 
Five cases of ILC had pathogenic CDH1 variants, of which one was novel, and none were 
found in the controls (P = 0.02), Supplementary Table 9. There was an association with 
age (case only analysis: =/< 40 years vs >40 years, OR = 13.14, 95% CI 2.19-78.75, P = 
0.02) but none with family history (case only with a first degree relative with breast cancer, 
OR = 2.95, 95% CI 0.49 -17.73, P = 0.24 or with any family history of breast cancer OR = 
2.11, 95% CI 0.35-12.65, P = 0.4) Table 2b. There was one variant found in a case of pure 
LCIS, and analysis of the pathology reports showed that all the cases except one had 
evidence of synchronous LCIS with the ILC and in four that the LCIS was bilateral, as 
described previously (21), Supplementary Table 9.  
 
BRCA1 and TP53  
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There was no evidence of an association with BRCA1, with just one frameshift deletion 
detected in exon 10 (c.2680_2681del:p.K894fs) in a patient aged 38 with bilateral LCIS, and 
ILC one breast and IDC and DCIS in the other, all ER positive.  
 
There were no TP53 variants detected in cases or controls.  
 
Variants of unknown significance  
There was no evidence of an excess of variants of unknown significance (VUS) in any of the 
genes including  rs35187787, a rare polymorphism in  CDH1 previously associated with 
breast cancer  (OR = 1.23, 95% CI 0.67-2.27, P = 0.54 for ILC), Supplementary Table 10.   
One variant in CHEK2 classified as having conflicting interpretations of pathogenicity, 
rs77130927 (exon4:c.C538T:p.R180C), was found in 7 ILC cases and 1 control and showed 
a borderline association with ILC, (OR = 7.89, 95% CI 0.97-64.27,P = 0.05). 
 
Bilateral Disease 
The cohort included 61 cases with pure bilateral lobular cancer of which 11.5% had 
pathogenic variants, four in CDH1, two in CHEK2 and one in BRCA2. There were 47 cases 
with ILC/LCIS in one breast and IDC/mixed invasive /DCIS in the contralateral breast, of 
which 8.5% had a pathogenic variant, two in BRCA2, one in CHEK2 and one in BRCA1. 
 
Discussion 
This is the first analysis of these six known breast cancer genes in an unselected population 
of ILC and LCIS and unlike other studies we have evaluated the entire coding region of each 
gene rather than focussing on a selected number of population specific variants.  
 
Although germline CDH1 variants have been extensively investigated in ILC, our study 
shows that the majority of rare germline variants found in women with ILC occur in BRCA2, 
PALB2, and CHEK2.  
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A previous study has shown that ILC does occur in 8.4% of BRCA2 variant carriers  (22) 
none have assessed the frequency of BRCA2 variants in a large cohort of cases purely of 
this special type. Our study shows that BRCA2 variants are the most common pathogenic 
variants found in ILC, with 7% of ILC cases under the age of 40 carrying a BRCA2 variant 
and 3% under the age of 50. The variants were distributed throughout the gene with no 
evidence of a lobular predisposition locus within the gene. Of the previously described 
variants only one was a known founder variant, 5946delT (found in two ILC cases), which 
has previously been associated with pancreatic and ovarian cancer (26). The known 
pathogenic missense variant D2723H was found in two women with ILC and has been 
shown to decrease RAD51 nuclear retention even when wild-type BRCA2 is present (27). 
 
The most frequent CHEK2 variant in European populations is the truncating  variant 
c.1100delC and this has been shown to confer a two fold increase in the risk of breast 
cancer (28,29). There is also a rare missense variant p.I157T (c.470 T > C, rs17879961) 
found in 0.005% of Non-Finnish European populations which is associated with a 1.4-fold 
elevation in breast cancer risk (30); this is classified as a risk allele rather than a pathogenic 
variant and thus is not included in the list of detected pathogenic CHEK2 variants in 
Supplementary Table 7. However this variant showed no association with ILC  in our data 
and was detected in 3 controls and 2 cases. 
 
 Two other truncating founder variants have been described in CHEK2, mainly in Polish 
populations: IVS2+1G>A and del5395 (29). The 5,395 bp founder deletion that removes 
exons 9 and 10 of the CHEK2 gene would not be detected using our technique, however the 
IVS2+1G>A, variant would be detected and was not present in this dataset.  
 
In previous publications p.I157T and c.1100delC carriers have been reported to be 
associated with phenotypically different types of breast cancer, with ILC being more 
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common in p.I157T carriers (31-33), and IDC in c.1100delC carriers (34). In our data p.I157T 
was not associated with lobular breast cancer and the most common variant found in 
CHEK2 was the c.1100delC variant, found in 1.3% of ILC cases in this study, a rate similar 
to the Breast Cancer Association Consortium (BCAC) study of 1100delC carriers, 1.2% in 
4,349 lobular cases (35). The association with p.I157T and lobular histology was originally 
identified from Polish series and subsequently in a large meta-analysis of p.I157T performed 
by BCAC where the majority (93%) of the cases again came from Germany/Poland/Finland 
/Sweden (31), suggesting this maybe a population specific finding. 
 
Due to the small number of pure LCIS we had limited power to detect associations with LCIS 
compared to ILC. CHEK2 was the only gene in our study where pathogenic variants were 
also associated with pure LCIS, particularly c.1100delC, with 3% of pure LCIS cases 
carrying a pathogenic variant. This has not been described in previous studies of the 
c.1100delC variant (32-34) although the 2016 BCAC study did show a greater association 
with in situ (mostly DCIS) tumors (35). The finding that CHEK2 variants were more strongly 
associated with pure LCIS than ILC suggests that CHEK2 variants maybe predisposing to 
the in situ stage of lobular cancer with not all progressing to the invasive stage. Of the 368 
pure LCIS cases in this study, only 37 have follow up data (median 81 months, range 34-
333) and 13 developed subsequent invasive breast cancer, 6 ipsilateral and 7 contralateral, 
as previously described (36). Two of the 13 pure LCIS cases that had developed 
subsequent invasive disease had pathogenic variants in CHEK2 and one a VUS in CHEK2 
(rs564605612), however a larger sample size with longer follow up would be required to 
ascertain whether germline variants in CHEK2 increase the risk of subsequent invasive 
disease after a diagnosis of pure LCIS. Germline variants in CHEK2 could explain the 
finding that invasive disease following a diagnosis of pure LCIS occurs with equal frequency 
in either breast and that these subsequent cancers can be in the form of ILC or IDC (7).  
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PALB2 was initially thought to be an intermediate risk cancer predisposition gene like 
CHEK2, but more recently the risk of breast cancer has been shown to be similar to that 
associated with BRCA2; Antoniou et al. reported a relative risk of 9.47 (95% CI 7.16 -12.57), 
compared to the general population breast-cancer incidence in the United Kingdom (37), 
similar to that found in the present study (OR 12.37). As 70% of breast cancers associated 
with germline PALB2 variants are ER positive (a similar frequency to that found in 
BRCA2 variants carriers and in sporadic breast cancer) it is not surprising that we have 
detected PALB2 variants in ILC. Previously, Cybulski et al. showed that 0.5% of ILC 
(7/1306) carried a PALB2 variant, however they only screened for the two variants common 
in Polish populations, 172_175delTTGT and c.509_510delGA (38).  
 
A previous study of germline PALB2 carriers (mainly the c.3113G>A variant) with invasive 
disease noted a borderline association with synchronous LCIS (39).  However, we identified 
only one individual with pure LCIS carrying a PALB2 truncating variant, rs180177132, in our 
cohort of 368 LCIS cases.  
 
Our previous study of CDH1 in 50 bilateral LCIS/ILC showed that 8% of bilateral lobular 
cases had pathogenic CDH1 variants (21). In this current study we have identified 61 cases 
of bilateral lobular cancer (the majority included in our previous study), and found that 11% 
carry pathogenic variants in CDH1, CHEK2 and BRCA2. Although we did not detect any 
new pathogenic CDH1 variants in the bilateral cases we did identify two in unilateral cases 
(one in ILC+LCIS and one in pure LCIS) giving a frequency of 0.1% in unilateral disease, 
confirming the result of other studies that germline pathogenic variants in CDH1 do not make 
a large contribution to the familial risk of unilateral lobular breast cancer. 
 
Current UK guidelines for BRCA1 and BRCA2 screening are based on a minimum combined 
probability of variant identification in 10% of cases. All women with triple negative breast 
cancer under 50 years of age are considered to meet this criterion however women of this 
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age with ER+ breast cancer are only eligible if they have a strong family history of breast 
cancer or are under the age of 30.  Although ILC aged 40 years or less is rare (71/1434, 5% 
of cases in this study) we have shown that 11% of these cases carry germline variants in 
known breast cancer susceptibility genes, particularly BRCA2 (7%) and CDH1 (3%). For 
women 50 years of age or less there was a 6% chance of having a germline variant and for 
women 60 years of age or less 5%, as variants in CHEK2 and PALB2 were not associated 
with younger age. It is likely that this is an underestimate as our methods will not detect 
some of the large deletions that have been described in BRCA2 (40).  
 
The lack of an association with age for PALB2 variants in our study is supported by the 
findings of Antoniou et al. who showed there was a constant relative risk, irrespective of age, 
for PALB2 (37). However, unlike our study, Schmidt et al did suggest that there is a 
relationship with age for the CHEK2 c.1100delC variant (35). PALB2 also did not show an 
association with family history of breast cancer and BRCA2 only a weak association unlike 
CHEK2 which showed a strong association with any family history of breast cancer but not 
with a history of a first degree relative with breast cancer. This is similar to the reports in 
pancreatic cancer series where most germline variants are found in patients without a 
significant family history of cancer (41). 
 
In conclusion this study has shown that CHEK2 variants are more frequent in LCIS than ILC. 
Although our study is too small to yield stable estimates of associations it gives useful 
estimates of prevalence in the UK population, suggesting that variants in this gene 
predispose to the in situ stage of lobular breast cancer. Longer follow up would be required 
to ascertain whether cases of pure LCIS with pathogenic CHEK2 variants develop invasive 
disease. We have also shown that variants in BRCA2, PALB2, and CHEK2 are more 
common in ILC than CDH1 variants, although CDH1 is still the most common germline 
variant in bilateral lobular cancer. Finally, we have demonstrated that women aged 40 years 
or less with ILC have an 11% chance of having a germline pathogenic variant indicating that 
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they should be offered genetic screening of BRCA2, CHEK2, PALB2, CDH1 and BRCA1 
under current UK guidance. As the majority of the invasive cancers associated with 
pathogenic mutations in CHEK2, PALB2 or CDH1 are ER positive, an alternative to risk 
reducing surgery would be chemoprevention and yearly screening with MRI, particularly for 
carriers of pathogenic CHEK2 variants which are associated with a lower risk of breast 
cancer than variants in the other genes. Our data do not support routine genetic testing for 
pure LCIS under 40 as the frequency of germline mutations is age independent (<60 years 
3.8%, <50 years 3.3%, <40 years 4.5%), with the exception of bilateral LCIS. However, if 
pathogenic germline variants in CHEK2 were found to identify a subset of LCIS more likely 
to develop invasive disease then genetic testing may be of value as it would identify a group 
of women with LCIS that would benefit most from chemoprevention. 
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TABLES 
Table 1: Association of known pathogenic variants with ILC and LCIS in women =/< 60 years 
of age by gene (1,434 ILC, 368 LCIS cases, 1,611 controls). 
 
Gene 
Pathogenic 
Variants in 
ILC Cases 
Pathogenic 
Variants in 
LCIS Cases 
Pathogenic 
Variants in 
Controls 
OR (95% CI) 
for ILC 
P value 
for ILC 
OR (95% CI) 
For LCIS 
P value 
for LCIS 
P-Value 
Case only 
(ILC vs LCIS) 
BRCA2 
27 1 2 
15.44  
(3.66-65.04) 1.7 x10-7 
2.19  
(0.20-24.24) 0.46 0.030 
CHEK2 
19 11 5 
4.31  
(1.61-11.58) 1.7 x10-3 
9.90  
(3.42-28.66) 1.4 x10-5 0.037 
PALB2 
11 1 1 
12.45  
(1.60-95.52) 2.2 x10-3 
4.39  
(0.27-70.30) 0.34 0.48 
CDH1 5 1 0 - 0.02 - 0.18 1.00 
BRCA1 1 0 0 - 0.5 - - - 
TP53 0 0 0 - - - - - 
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Table 2a: Case only analysis of pathogenic variants in ILC by age. 
 
  Carriers </=40 vs >40 Carriers </=50 vs 51-60 
Gene OR (95% CI) P OR (95% CI) P 
BRCA2 4.62 (1.74-12.23) 0.009 4.83 (1.95-12.01) 0.0003 
CHEK2 0.00 (0.00-0.00) 0.62 0.78 (0.31-1.99) 0.65 
PALB2 0.00 (0.00-0.00) 1 1.12 (0.34-3.68) 1 
CDH1 13.14 (2.19-78.75) 0.022 2.02 (0.34-12.1) 0.66 
BRCA1 - 0.05 - 0.43 
TP53 - - - - 
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Table 2b: Case only analysis of pathogenic variants in ILC for family history (FH) of breast 
cancer (BC) 
 
  
Carriers FH of BC vs no FH 
in first degree relative 
Carriers FH of BC vs no FH in 
Any relative  
Gene OR (95% CI) P OR (95% CI) P 
BRCA2 2.36 (1.05-5.31) 0.043 2.25 (1.02-4.98) 0.046 
CHEK2 2.59 (1.02-6.60) 0.067 3.95 (1.42-11.01) 0.008 
PALB2 2.94 (0.83-10.45) 0.097 3.26 (0.84-12.65) 0.105 
CDH1 2.95 (0.49-17.73) 0.238 2.11 (0.35-12.65) 0.415 
BRCA1 0 1 - 0.419 
TP53 - - - - 
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FIGURE LEGEND 
Figure 1: Position of pathogenic variants 
Figure 1 shows the position of pathogenic variants in (a) BRCA2, (b) CHEK2, (c) PALB2, (d) 
CDH1 (black = case, green = control) 
 
